The Real Business of Collagen Supplements Is Not What the Bottles Say

THE BOTTLE promises a lot. PureHealth Research's Marine Collagen Booster, a dietary supplement built around a branded ingredient called Morikol®, claims to support skin hydration, elasticity, wrinkle reduction, joint comfort, hair strength and healthy aging. It is manufactured in cGMP-certified U.S. facilities, its ingredients are non-GMO and third-party tested, and the company boasts a 365-day money-back guarantee. It has sold, it says, almost 12 million bottles.

The fine print tells a more instructive story. The product has "not been independently tested for efficacy or safety." Each ingredient, PureHealth Research notes, has been "scientifically studied" individually. That is a meaningful distinction. A bottle of combined ingredients that has never been tested as a formula is not the same thing as one that has.

The broader lesson is worth examining because the collagen-supplement market is no longer a niche wellness curiosity. It was worth $5.91 billion in 2025 and is projected to reach $8.02 billion by 2030, according to Mordor Intelligence. The collagen-peptides sub-segment alone is growing at a 10.5% compound annual rate, Data Bridge Market Research calculates. Investors in consumer health, nutraceutical supply chains, and the ingredient companies that sit beneath these brands need to understand what is driving the growth, where the value is captured, and whether the science can bear the weight of the marketing.

The answer to the first question is clear: the value is not captured by the private-label brand on the front of the bottle. It is captured by the ingredient supplier on the back.

Morikol is made by DolCas Biotech, a New Jersey-based nutraceutical company that sells a marine collagen tripeptide derived from fish. The molecules are very small — roughly 300 daltons (the mass unit used to measure molecules), which is a fraction of the size of conventional collagen peptides and, DolCas claims, allows for absorption through intestinal transporters called PEPT1 receptors. The company's CEO, G Rao, has been actively pitching Morikol at industry trade shows and securing partnerships with distributors, including a deal with ACI Group in September 2025. DolCas has also released the ingredient in new formats — single-serving sachets in April 2026 and, more colorfully, collagen-infused chocolate bars in July 2025.

DolCas is the engine. PureHealth Research, Vital Proteins, and dozens of other consumer brands are distribution channels. That supplier-driven architecture is not unusual in nutraceuticals, but it is important. It means the companies worth watching are not the ones advertising on Amazon; they are the ones selling ingredients to the advertisers.

The science is where the narrative becomes thinner.

DolCas points to three studies to support Morikol's claims: a 2018 trial in the journal Nutrients finding improvements in skin hydration and elasticity, a 2015 study on knee osteoarthritis, and a 2012 animal study on UV damage in hairless mice. One of those three is in mice. The others are small, industry-associated studies that measure outcomes such as "wrinkle visual scores" rather than clinically meaningful endpoints.

The broader literature on collagen supplements is more illuminating — and considerably less flattering. A 2025 meta-analysis published in the American Journal of Clinical Nutrition examined 23 randomised controlled trials, totalling 1,474 participants, and stratified results by funding source. The finding was stark. Studies funded by pharmaceutical or supplement companies showed significant improvements in hydration, elasticity and wrinkles. Studies that were not industry-funded showed no effect. High-quality studies found no significant benefit across any measured category. Low-quality studies showed improvements, particularly in elasticity.

To be sure, collagen supplements are not entirely without evidence. A 2023 meta-analysis of 26 trials by Pu and colleagues found modest overall improvements in skin metrics, and a 2026 umbrella review in Aesthetic Surgery Journal Open Forum classified the evidence for dermal, bone and muscular benefits at "Level of Evidence 3" — a rating that, in clinical parlance, is suggestive rather than definitive. Even the strongest published trial of a branded marine collagen product, a 2026 study of "Absolute Collagen" funded by the manufacturer itself, reported that benefits reversed within eight weeks of stopping supplementation. Discontinue the pills and the effect fades.

The trouble is not that collagen supplements are a scam. The trouble is that the evidence supporting them looks precisely what one would expect if the people funding the research had an interest in the result.

This is worth emphasizing for anyone evaluating companies in this space. The global collagen-supplement industry is highly fragmented — Mordor Intelligence classifies market concentration as low — and it is growing because of real structural tailwinds: aging populations, the so-called "beauty-from-within" trend among younger consumers, and the shift from topical to ingestible solutions. Rousselot, the French ingredient giant, held an 18.2% share of the fish-collagen market in 2025. Glanbia Nutritionals recently launched Collameta, a tripeptide it claims has four times faster absorption than conventional peptides. Evonik entered the field with Vecollan, a fermentation-based collagen that sidesteps animal-derived sourcing.

These are the companies that matter. They own the formulations, the clinical studies and the distribution relationships. Private-label brands like PureHealth Research compete on marketing, pricing and customer service. They are, structurally, interchangeable.

The consumer side of the equation is no accident. PureHealth Research sells exclusively through its own website, bundles products into 90-day and 180-day subscription packages and offers a year-long refund guarantee. It also helps customers obtain a Letter of Medical Necessity — at a cost of $15, processed through a partner called Flex — so the product can be purchased with Health Savings Account or Flexible Spending Account funds. None of this is fraudulent. It is a well-designed direct-to-consumer funnel that reduces churn, increases lifetime value and leverages tax-advantaged spending accounts. The business model is the innovation, not the peptide.

For investors, the relevant risk is the opposite one: confusing marketing innovation with scientific differentiation. A brand that has not independently tested its own formula, that relies on an ingredient manufacturer's studies conducted under favourable conditions, and that sits in a market where independent meta-analyses find no effect from non-industry-funded trials — such a brand can grow, certainly, but its moat is customer acquisition, not collagen.

The better play is upstream. The companies that own the peptide formulations, the clinical data and the contracts with fifty white-label brands will profit regardless of which consumer name trends on social media. The ingredient suppliers are the real winners in a market where the science is thin, the marketing is thick and the distribution architecture is designed to make the supplier the last person to lose.

Collagen supplements will keep selling. The question is not whether consumers will buy them. It is who gets paid first.